Summary

For patients with breast cancer who undergo primary surgery, sentinel lymph node biopsy (SLNB) is the standard staging procedure to determine the axillary status when the patient is clinically node negative [D'Angelo-Donovan DD et al. Surg Oncol 2012]. However, for patients who undergo neoadjuvant chemotherapy, the optimal role and timing of SLNB is still unclear. This article presents final results from the prospective German, multi-institutional Sentinel Neoadjuvant [SENTINA] trial.